Evgen Pharma plc Stock price

Equities

EVG

GB00BSVYN304

Biotechnology & Medical Research

Delayed London S.E. 08:38:16 2024-03-28 am EDT 5-day change 1st Jan Change
0.86 GBX -1.71% Intraday chart for Evgen Pharma plc -11.79% -46.25%
Sales 2024 * 486K Sales 2025 * - Capitalization 3.04M
Net income 2024 * -4M Net income 2025 * - EV / Sales 2024 * 1.75 x
Net cash position 2024 * 2.19M Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.7 x
P/E ratio 2025 *
-
Employees 10
Yield 2024 *
-
Yield 2025 *
-
Free-Float 59.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.71%
1 week-11.79%
Current month-9.47%
1 month-18.10%
3 months-46.25%
6 months-59.05%
Current year-46.25%
More quotes
1 week
0.81
Extreme 0.81
0.96
1 month
0.81
Extreme 0.81
1.10
Current year
0.81
Extreme 0.81
2.00
1 year
0.81
Extreme 0.81
4.05
3 years
0.81
Extreme 0.81
9.50
5 years
0.81
Extreme 0.81
24.35
10 years
0.81
Extreme 0.81
45.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO - 23-09-04
Chief Tech/Sci/R&D Officer - 21-04-30
Members of the board TitleAgeSince
Chief Executive Officer 62 -
Chairman 71 14-11-20
Director/Board Member - 15-10-20
More insiders
Date Price Change Volume
24-03-28 0.86 -1.71% 21 978
24-03-27 0.875 0.00% 1,185,440
24-03-26 0.875 0.00% 2,281,489
24-03-25 0.875 -7.89% 2,359,794
24-03-22 0.95 -2.56% 1,417,725

Delayed Quote London S.E., March 28, 2024 at 08:38 am EDT

More quotes
Evgen Pharma plc is a United Kingdom-based clinical-stage drug development company. The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. The Company's core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane's activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Evgen Pharma plc - London S.E.